CLINICAL TRIALS PROFILE FOR SODIUM IODIDE I-123
✉ Email this page to a colleague
All Clinical Trials for SODIUM IODIDE I-123
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00450814 ↗ | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2006-11-30 | This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma. |
| NCT00450814 ↗ | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | Completed | Mayo Clinic | Phase 1/Phase 2 | 2006-11-30 | This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma. |
| NCT00638092 ↗ | A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years | Completed | National Institute for Health Research, United Kingdom | Phase 4 | 2010-03-01 | The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age. |
| NCT00638092 ↗ | A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years | Completed | University of Dundee | Phase 4 | 2010-03-01 | The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age. |
| NCT00638092 ↗ | A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years | Completed | University of Oxford | Phase 4 | 2010-03-01 | The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SODIUM IODIDE I-123
Condition Name
Clinical Trial Locations for SODIUM IODIDE I-123
Trials by Country
Clinical Trial Progress for SODIUM IODIDE I-123
Clinical Trial Phase
Clinical Trial Sponsors for SODIUM IODIDE I-123
Sponsor Name
